@DrugChannels @YohoPharmD @contirena1 @USGAO “an

@DrugChannels @YohoPharmD @contirena1 @USGAO “and how the PBMs are going to maximize their own profits to save mone… https://t.co/AVCVxlhggg

CAPhO Virtual Conference 2021 starts tomorrow at 7

CAPhO Virtual Conference 2021 starts tomorrow at 7:15pm EDT with a sponsored Symposium presented by Pfizer titled ‘… https://t.co/evchjaOXHC

@charlie_lees @Patrick_C_Esq Also I think that cost of goods is likely to remain relatively high for biosimilars be… https://t.co/efvyGBljy1

A mighty day for the parish! Roll on new treatment 💉💉 #crohnsdisease https://t.co/dG3FlQF6re

I’m still recovering but I’m starting to feel a bit better with these antibiotics. Being taken off Humira and being… https://t.co/lGAlFB8J1d

Among the many potential benefits of introducing biosimilars is the opportunity to help generate cost-savings in he… https://t.co/aPbeKjllFp

@Patrick_C_Esq This is 10-15% the price of the originator. Savings in the order of 90% are pretty extraordinary in… https://t.co/FkQxbXMy2s

#crohnsdisease update. Prednisone is a miracle drug! Feel better than I have in months. Not a permanent solution bu… https://t.co/yZcnTdZiG6

On 12/06 @Marie_L_Hall is walking 26 miles to raise funds for a cause close to her heart. We walking with her to su… https://t.co/UZWOP0iP9x

Phase 3 Maintenance Results Show Patients with Crohn’s Disease Receiving Risankizumab (SKYRIZI®) Achieved Endoscopi https://t.co/uK2xKhlGty